|
Market Closed -
Other stock markets
|
After hours 00:00:00 | |||
| 0.6480 EUR | +5.88% |
|
0.6500 | +0.31% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| Revenues (N-1) | Net Margin (N-1) | EBIT Margin (N-1) | ROE (N-1) | ROA (N-1) | Leverage (N-1) | ||
|---|---|---|---|---|---|---|---|
 | 1.38M | - | 54.43% | - | - | - | |
| 65.01B | 28.08% | 41.19% | 45.52% | 17.73% | 1.07x | |
| 24.78B | 12.36% | 17.06% | 12.4% | 5.06% | 1.51x | |
| 1.4B | 22.69% | 33.58% | 153.59% | - | 3.59x | |
| 3.17B | 13.49% | 20.59% | 7.7% | 8.02% | -1.69x | |
| 490M | 37.77% | 28.86% | 39.28% | 22.66% | -1.18x | |
| 1.51B | 8.48% | 4.77% | 8.21% | 6.3% | -0.32x | |
| 516M | 8.46% | 11.59% | 5.02% | - | 2.04x | |
| 719M | -5.36% | 22.07% | 12.89% | - | - | |
| 79.95M | -5.75% | -1.06% | - | - | - | |
| 613M | 14.15% | -3% | 6.3% | -0.45% | -30.97x | |
| 84.61M | -45.97% | -61.26% | -6.62% | -5.3% | - | |
| Average | 8.2B | 8.03% | 14.07% | 28.43% | 7.72% | -3.24x | |
| Weighted average by Cap. | 52.86B | 24.26% | 35.26% | 40.51% | 15.15% | 1.04x |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
